Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: January 17, 2007
Last updated: October 13, 2010
Last verified: October 2010
Data suggests that imaging activity of the brain can measure the effects of anti-anxiety drugs. This study will investigate the effect of GW876008 on areas of the brain involved with thinking and emotion

Condition Intervention Phase
Healthy Subjects
Drug: placebo
Drug: lorazepam
Drug: GW876008
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Differences in brain activation elicited by Matching Emotional Face Expression paradigm following single oral doses of GW876008 and lorazepam on day 1, sessions 1-4

Secondary Outcome Measures:
  • GW876008 blood levels [ Time Frame: pre-dose & post-dose, sessions 1-4 ]
  • clinical rating scales change after dosing: questionnaires collected [ Time Frame: pre-dose & up to 6-8 hours post-dose. ]
  • Safety: 12-lead ECG, vital signs, adverse events, clinical labs
  • fMRI BOLD neuroanatomical structure of the emotional brain neurocircuitry and connectivity
  • fMRI BOLD Signal characteristics and connectivity
  • fMRI BOLD Response in the emotional brain neurocircuitry and occipital cortex.
  • ETCo2 in mm Hg, to be recorded for the duration of the scan session and be synchronized with the single fMRI procedure timing
  • Visual Analog Scale (VAS) measurements of sleepiness, alertness, calm, tension, and anxiety performed before dosing (baseline), pre-fMRI session, post-fMRI session and just before leaving the facility.
  • Association between the anxiety trait (STAI-trait, test battery for neuroticism or liability for Anxiety Disorders) collected at screening and the various pharmacodynamic parameters measured in the various testing conditions.
  • GW876008 concentration to determine pharmacokinetic parameters to be collected twice per session,
  • Pharmacogenetic (PGx) assessments
  • Safety and tolerability of GW876008 to include Vital signs semi-supine; respiratory rate, pulse oximetry and ECG.
  • Clinical laboratory tests
  • fMRI BOLD ALS signal.
  • Heart rate (HR; beats per minute), to be recorded for the whole duration of the scan session and to be synchronized with the single fMRI procedure timing.
  • Respiratory rate (RR: inspiration per minute), to be recorded for the duration of scan session and be synchronized with the single fMRI procedure timing. .

Enrollment: 26
Study Start Date: March 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: placebo Drug: lorazepam Drug: GW876008
    Other Names:
    • placebo
    • lorazepam

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males or females aged 18-50 years, inclusive.
  • STAI-trait score = or > 40.
  • STAI-state score <50th percentile of the normal population distribution.
  • Female subjects of non-childbearing.
  • Female subjects of childbearing potential must agree to use appropriate contraception.
  • Healthy subjects, as determined by a responsible physician
  • Body weight ≥ 50 kg (110 lbs), and BMI within the range 19-29.9 kg/m2 inclusive.
  • Demonstrates no significant evidence of active disease, physical or mental impairment when assessed by qualified personnel
  • Non-smoker (abstinence from smoking for at least 6 months before the start of the study).
  • Normal electrocardiogram.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Read, comprehend, and write English at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation

Exclusion Criteria:

  • As a result of any of the medical interview, physical examination, evaluation of mental state and psychiatric history or screening investigations the physician responsible considers the subject unfit for the study.
  • Any history of suicidal attempts or behaviour.
  • Any history or current diagnosis of a psychiatric illness.
  • Any history of an endocrine disorder including, but not limited to, diabetes or disorders of the hypothalamus, pituitary, adrenal, or thyroid glands, or gonadal disorder or dysfunction of the reproductive organs.
  • Abnormal pepsinogen I level at screening.
  • Liver Function Tests (LFTs) elevated above the reference range at pre-study screening that remain elevated with a repeat LFT
  • Any other clinically significant laboratory abnormality.
  • Positive faecal occult blood test.
  • Positive pre-study urine drug/alcohol breath screen.
  • Positive pre-study HIV 1/2, Hepatitis B surface antigen and positive Hepatitis C antibody result within 3 months of the start of the study.
  • Pre-existing or current Helicobactor pylori infection.
  • History of alcohol/drug abuse or dependence within 12 months of the study
  • Consumption of grapefruit juice or grapefruit within 14 days prior to the first dose of study medication.
  • History of peptic ulcer disease.
  • Abnormal screening ECG
  • History of long QT syndrome (personal or family) or other cardiac conduction disorder, or other clinically significant cardiac disease.
  • Systolic blood pressure < 90mmHg or >140mmHg; diastolic blood pressure < 60mmHg or > 90mmHg; pulse rate < 40bpm or > 90bpm.
  • Participation in a clinical trial with a drug or new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History or current diagnosis of acute narrow angle glaucoma.
  • Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period.
  • Current or recent (within one year) gastrointestinal disease; a history of malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a week) occurrence of heartburn; or any surgical intervention (e.g., cholecystectomy) which would be expected to influence the absorption of drugs.
  • Average daily caffeine intake equivalent to > 4 cups of coffee or > 6 cups of tea.
  • Subjects who are left handed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00424697

United States, California
GSK Investigational Site
La Jolla, California, United States, 92093
Sponsors and Collaborators
Study Director: GSK Clinical Trials, MBChB, MFPM GlaxoSmithKline
  More Information

Responsible Party: Study Director, GSK Identifier: NCT00424697     History of Changes
Other Study ID Numbers: CRH104150
Study First Received: January 17, 2007
Last Updated: October 13, 2010

Keywords provided by GlaxoSmithKline:
Brain imaging,
healthy subjects

Additional relevant MeSH terms:
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017